Bioqual (OTCMKTS:BIOQ) Trading Down 3.8% – Should You Sell?

Bioqual Inc. (OTCMKTS:BIOQ)’s share price was down 3.8% during trading on Tuesday . The stock traded as low as $38.50 and last traded at $38.50. Approximately 208 shares changed hands during mid-day trading, an increase of 15,900% from the average daily volume of 1 shares. The stock had previously closed at $40.00.

Bioqual Stock Performance

The business has a 50-day moving average of $38.75 and a 200-day moving average of $40.90. The stock has a market capitalization of $34.27 million, a price-to-earnings ratio of -55.00 and a beta of -0.19.

Bioqual (OTCMKTS:BIOQ) last posted its earnings results on Tuesday, October 21st. The company reported ($0.28) EPS for the quarter. The company had revenue of $9.85 million during the quarter. Bioqual had a negative net margin of 1.32% and a negative return on equity of 1.73%.

Bioqual Company Profile

Bioqual, Inc is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds.